Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes -- Ignore unavailable to you. Want to Upgrade?

To: Lawrence Burg who wrote (3184)	3/30/1998 1:41:00 AM
From: Zakattack	Respond to of 34592

Strange development... Since Joe did not send out that fake EM, I wonder if people abandoned ship too soon? (IMO) BANY might gap up this morning! Message 3882919 R, Z

To: Lawrence Burg who wrote (3184)	3/30/1998 8:35:00 AM
From: Bradpalm1	Respond to of 34592

I wouldn't jump blindly on the SCLN bandwagon just yet. Good initial results from their Zadaxin Phase II study of 12 liver cancer patients look promising but this was only over a 6 month time period. Further, results from their Phase III studies for treatment of chronic hepatitis B and C look less than exciting. This stock may continue to rise in the short-term but the long-term investment potential of this company is still very questionable. More details to follow. Bradpalm1

To: Lawrence Burg who wrote (3184)	4/2/1998 3:39:00 PM
From: Charles J	Read Replies (1) \| Respond to of 34592

SciClone Completes $4 Million Equity Financing with conversion prices at a hefty premium. I wonder if they know something. It is already selling in three countries with pending approvals in at least 15 others. What does Secret Squirrel know. Is he/she still accumulating? This is an excerpt from the release in yahoo. "SciClone issued 661,157 preferred shares at a price of $6.05 per share, a premium of approximately 57% over the closing bid price of the Company's common stock on the closing date (April 1, 1998). The preferred shares pay no dividends and are convertible into common stock on a scheduled basis over the next five years at prices based on the market price of the common stock during a pricing period preceding conversion. The investors also received 100,000 five-year warrants to purchase common stock at $5.67 per share. If the investors convert their preferred shares at a price exceeding $6.00 per share, they will receive the right to purchase additional shares of common stock at a price no less than $6.00 per share, which if fully exercised, would result in additional proceeds to the Company of not less than $3.96 million. Reedland Capital Partners, a division of the Financial West Group, acted as placement agent."